Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
University of Florida
Children's Hospital of Philadelphia
University of Florida
Memorial Sloan Kettering Cancer Center
Emory University
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Memorial Sloan Kettering Cancer Center
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Princess Maxima Center for Pediatric Oncology
St. Jude Children's Research Hospital
University of Alberta
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Baylor College of Medicine
Sun Yat-sen University
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
Children's Hospital Los Angeles
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Children's National Research Institute
Mayo Clinic
Baylor College of Medicine
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
Mayo Clinic
Baylor College of Medicine
Memorial Sloan Kettering Cancer Center
Children's Hospital of Philadelphia
Emory University
Children's Hospital of Philadelphia
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
Beijing Children's Hospital
New Approaches to Neuroblastoma Therapy Consortium
Seattle Children's Hospital
Seattle Children's Hospital
Institut Claudius Regaud
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital